%0 Generic %C [S.l.] : %D 2016. %I Canadian Agency for Drugs and Technologies in Health, %T CADTH Canadian Drug Expert Committee Final Recommendation Omalizumab- Resubmission (Xolair- Novartis Pharmaceuticals Canada Inc.): Indication: Asthma. %U http://SK8ES4MC2L.search.serialssolutions.com/?sid=sersol&SS_jc=TC_035307812&title=CADTH%20Canadian%20Drug%20Expert%20Committee%20Final%20Recommendation%20Omalizumab-%20Resubmission%3A%20%28Xolair-%20Novartis%20Pharmaceuticals%20Canada%20Inc.%29%3A%20Indication%3A%20Asthma